Ibcasertib
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Ibcasertib is an investigational new drug that is being evaluated to treat small-cell lung cancer. Ibcasertib inhibits several angiogenesis-related kinases, including VEGFR1, VEGFR2, VEGFR3, PDGFRα, and c-Kit, as well as the mitosis-related kinase Aurora B and the chronic inflammation-related kinase CSF-1R.
Ibcasertib is an investigational new drug that is being evaluated to treat small-cell lung cancer. Ibcasertib inhibits several angiogenesis-related kinases, including VEGFR1, VEGFR2, VEGFR3, PDGFRα, and c-Kit, as well as the mitosis-related kinase Aurora B and the chronic inflammation-related kinase CSF-1R.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1374610425 under CC BY-SA 4.0; modifications have been made.